Model-based impact and cost-effectiveness of cervical cancer prevention in sub-saharan Africa

Vaccine

Volumn 31, Issue S5, 2013, Pages

  Kim, Jane J ^a   Campos, Nicole G ^a,b   O'Shea, Meredith ^a   Diaz, Mireia ^c   Mutyaba, Innocent ^d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

Author keywords

Cost effectiveness; HPV; Mathematical model; Sub Saharan Africa

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; CAMEROON; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEMOCRATIC REPUBLIC CONGO; ETHIOPIA; FEMALE; GROUPS BY AGE; HEALTH CARE COST; HUMAN; KENYA; MAJOR CLINICAL STUDY; MOZAMBIQUE; NIGERIA; OUTCOME ASSESSMENT; POPULATION SIZE; POPULATION STRUCTURE; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK REDUCTION; TANZANIA; UGANDA; UTERINE CERVIX CANCER; VACCINATION;

COST-EFFECTIVENESS; HPV; MATHEMATICAL MODEL; SUB-SAHARAN AFRICA;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; CHILD; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK REDUCTION BEHAVIOR; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84890093808     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.093     Document Type: Review

References (55)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer incidence and mortality worldwide. IARC CancerBase No. 10 [Internet]. Lyon, France: IARC; 2010. Available at: (last accessed July 2011). http://globocan.iarc.fr/.
2. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in Africa. Summary Report 2010. Available at: (last accessed December 2011). http://www.hpvcentre.net/.
3. Department of Health, Republic of South Africa. National Guideline on Cervical Cancer Screening Programme. Available at: (last accessed December 2011). http://www.doh.gov.za/docs/factsheets/guidelines/cancer.pdf.
4. Sankaranarayanan R., Esmy P.O., Rajkumar R., Muwonge R., Swaminathan R., Shanthakumari S., et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu. India: a cluster-randomised trial, Lancet 2007, 370:398-406.
5. Sankaranarayanan R., Nene B., Shastri S.S., Jayant K., Muwonge R., Budukh A.M., et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009, 360:1385-1394.
6. Sankaranarayanan R., Nessa A., Esmy P.O., Dangou J.M. Visual inspection methods for cervical cancer prevention. Best Pract Res Clin Obstet Gynaecol 2012, 26(2):221-232.
7. Goldie S.J., Gaffikin L., Goldhaber-Fiebert J.D., Gordillo-Tobar A., Levin C., Mahé C., et al. Alliance for Cervical Cancer Prevention Cost Working Group, Cost-effectiveness of cervical cancer screening in five developing countries. N Engl J Med 2005, 353:2158-2168.
8. Mwanahamuntu M.H., Sahasrabuddhe V.V., Kapambwe S., Pfaendler K.S., Chibwesha C., Mkumba G., et al. Advancing cervical cancer prevention initiatives in resource-constrained settings: insights from the Cervical Cancer Prevention Program in Zambia. PLoS Med 2011, 8(5):e1001032.
9. Gage J.C., Ajenifuja K.O., Wentzensen N.A., Adepiti A.C., Eklund C., Reilly M., et al. The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: Implications for screen-and-treat strategies. Int J Cancer 2011, 130:2111-2117.
10. Kagire E. First Lady to launch anti-cervical cancer campaign. The New Times April 26, 2011. Available at: (last accessed December 2011). http://www.newtimes.co.rw/index.php%3Fissue=14607%26article=40560.
11. GAVI Alliance Countries eligible for support. Available at: (last accessed July 2011). http://www.gavialliance.org/support/apply/countries-eligible-for-support/.
12. World Bank World Development Indicators. Available at: (last accessed December 2011). http://data.worldbank.org/data-catalog/world-development-indicators.
13. World Health Organization (WHO). Statistical Information System: CHOICE (CHOosing Interventions that are Cost Effective). Available at: (last accessed December 2011). http://www.who.int/choice/en/.
14. Goldie S.J., Kuhn L., Denny L., Pollack A., Wright T.C. Policy analysis of cervical cancer screening strategies in low-resource settings - Clinical benefits and cost-effectiveness. JAMA 2001, 285(24):3107-3115.
15. Campos N.G., Kim J.J., Castle P.E., Ortendahl J., O'Shea M., Diaz M., et al. Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. Int J Cancer 2012, 130(11):2672-2684.
16. Disease Control Priorities Project (DCPP). Available at: (last accessed April 2008). http://www.dcp2.org/main/Home.html.
17. Methods for the economic evaluation of health care programs. 2005, Oxford University Press, New York. 3rd Edition. M.F. Drummond, M.J. Sculpher, G.W. Torrance, B.J. O'Brien, G.L. Stoddart (Eds.).
18. World Health Organization (WHO). Macroeconomics and health: investing in health for economic development: report of the commission on macroeconomics and health. Geneva:World Health Organization, 2001.
19. Goldie S.J., O'Shea M.K., Campos N.G., Diaz M., Sweet S.J., Kim S.Y. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008, 26(32):4080-4093.
20. Goldie S.J., Diaz M., Kim S.Y., Levin C.E., Minh H.V., Kim J.J. Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine 2008, 26(S12):M17-M29.
21. Goldie S.J., Diaz M., Constenla D., Alvis N., Andrus J.K., Kim S.Y. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine 2008, 26(S11):L59-L72.
22. United Nations (UN), Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2008 Revision. CD-ROM Edition - Extended Dataset (United Nations publications, Sales No. E.05.XIII.12).
23. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. on behalf of the Retrospective International Survey and HPV Time Trends Study Group, Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(11):1048-1056.
24. World Health Organization (WHO). Life tables for WHO member states: 2009. Available at: (last accessed July 26, 2011). http://www.who.int/healthinfo/statistics/mortality_life_tables/en/.
25. Diaz M., Kim J.J., Albero G., de Sanjose S., Clifford G., Bosch F.X., et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008 Jul 22, 99(2):230-238.
26. Goldie S.J., Kim J.J., Kobus K., Goldhaber-Fiebert J.D., Salomon J., O'Shea M.K.H., et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007, 25:6257-6270.
27. Kim J.J., Kuntz K.M., Stout N.K., Mahmud S., Villa L.L., Franco E.L., et al. Multi-parameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007, 166:137-150.
28. Diaz M., de Sanjose S., Ortendahl J., O'Shea M., Goldie S.J., Bosch F.X., et al. Cost-effectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer 2010 Nov, 46(16):2973-2985.
29. Sharma M., Ortendahl J., van der Ham E., Sy S., Kim J.J. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. BJOG 2011 Jan, 119(2):166-176.
30. Kim J.J., Kobus K.E., Diaz M., O'Shea M., Van Minh H., Goldie S.J. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine 2008 Jul 29, 26(32):4015-4024.
31. Acharya A., Diaz-Ortega J.L., Tambini G., de Quadros C., Arita I. Cost-effectiveness of measles elimination in Latin America and the Caribbean: a prospective analysis. Vaccine 2002, 20(27-28):3332-3341.
32. Kou U. Guidelines for estimating costs of introducing new vaccines into the national immunization system 2002, World Health Organization, Department of Vaccines and Biologicals, Geneva.
33. Walker D., Mosqueira N.R., Penny M.E., Lanata C.F., Clark A.D., Sanderson C.F., et al. Variation in the costs of delivering routine immunization services in Peru. Bull World Health Organ 2004, 82(9):676-682.
34. Wolfson L.J., Gasse F., Lee-Martin S.P., Lydon P., Magan A., Tibouti A., et al. Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015. Bull World Health Organ 2008, 86(1):27-39.
35. Goldhaber-Fiebert J.D., Goldie S.J. Estimating the cost of cervical cancer screening in five developing countries. Cost Eff Resour Alloc 2006, 4:13.
36. World Health Organization (WHO). Alphabetical list of WHO member states. Available at: (last accessed July 25, 2011). http://www.who.int/choice/demography/by_country/en/index.html.
37. Central Intelligence Agency (CIA). The World Factbook. Available at: (last accessed June 2012). https://www.cia.gov/library/publications/the-world-factbook/.
38. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. CVT Vaccine Group, Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103(19):1444-1451.
39. Kim J.J., Goldie S.J. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008, 359(8):821-832.
40. Kim J.J., Goldie S.J. Cost-effectiveness analysis of including boys in a human papillomavirus (HPV) vaccination programme in the United States. BMJ 2009, 339:b3884.
41. Qiao Y., Sellors J.W., Eder P.S., Bao Y., Lim J.M., Zhao F., et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008, 9:929-936.
42. Ogilvie G.S., Patrick D.M., Schulzer M., Sellors J.W., Petric M., Chambers K., et al. Diagnostic accuracy of self-collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sex Transm Infect 2005, 81:207-212.
43. World Health Organization (WHO). Global health expenditures database, 2009. Available at: (last accessed December 2011). http://apps.who.int/nha/database/StandardReport.aspx%3FIDY=YREPORT_6_REGIONAL_AVERAGES%23.
44. Canfell K., Kulasingam S.L., Berkhof J., Diaz M., Chesson H., Kim J.J. Modeling preventative strategies in developed countries. Vaccine 2013, 31(Suppl 3).
45. Chesson H.W., Ekwueme D.U., Saraiya M., Dunne E.F., Markowitz L.E. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011, 29:8443-8450.
46. Kim S.Y., Salomon J.A., Goldie S.J. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bull WHO 2007, 85:833-842.
47. Akumu A.O., English M., Scout J.A.G., Griffiths U.K. Economic evaluation of delivering Haemophilus influenzae type b vaccine in routine immunization services in Kenya. Bull World Health Organ 2007, 85:511-518.
48. Kim S.Y., Sweet S., Chang J., Goldie S.J. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden. BMC Infect Dis 2011, 11:174.
49. UNAIDS: Uganda Available at: (last accessed on May 2012). http://www.unaids.org/en/regionscountries/countries/uganda/.
50. UNAIDS: South Africa Available at: (last accessed on May 2012). http://www.unaids.org/en/regionscountries/countries/southafrica/.
51. Levin M.J., Moscicki A., Song L-Y., Fenton T., Meyer W.A., Read J.S., et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010, 55(2):197-204.
52. Averbach S.H., Gravitt P.E., Nowak R.G., Celentano D.D., Dunbar M.S., Morrison C.S., et al. The association between cervical human papillomavirus infection and HIV acquisition among women in Zimbabwe. AIDS 2010, 24:1035-1042.
53. Smith-McCune K.K., Shiboski S., Chirenje S.E., Magure T., Tuveson J., Ma Y., et al. Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS One 2010, 5:e10094.
54. Veldhuijzen N.J., Vyankandondera J., van de Wijgert J.H. HIV acquisition is associated with prior high-risk human papillomavirus infection among high-risk women in Rwanda. AIDS 2010, 24:2289-2292.
55. Kuhn L., Wang C., Tsaie W-Y., Wright T.C., Denny L. Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women. AIDS 2010, 24:2253-2261.